T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate T-20 in children.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Collaborator: Trimeris
• Treatments: Enfuvirtide

Criteria

Inclusion Criteria

Patients may be eligible for this study if they:

• Are 3 through 16 years of age and have the consent of parent or guardian.

• Have a viral load of at least 5000 copies/ml.

• Have taken at least 2 of the 3 licensed anti-HIV drug classes for at least 3 months.

• Have been on stable therapy for at least 4 weeks.